Transformative Therapies

Transformative Therapies

Accelerating high-impact discovery to transform outcomes in the hardest-to-treat childhood cancers

Childhood cancers with the poorest survival rates and most intensive treatment regimens urgently need new solutions. Existing therapies can be ineffective for cancers that relapse, spread or resist standard treatment, and can cause serious, lifelong harm to children’s developing bodies.

Our Transformative Therapies Impact Program invests in blue-sky and high-impact research to accelerate breakthrough therapies for childhood cancers with the greatest unmet need, prioritising more targeted, more effective, and less toxic treatment options.

In addition to larger project grants, our seed grants support bold, early-stage projects, providing researchers with the resources to generate critical proof-of-concept data and unlock larger-scale funding.

Together, our strategic investments aim to transform the treatment landscape for high-risk, relapsed, refractory and metastatic childhood cancers, so every child has access to therapies that improve survival while protecting long-term health and quality of life.

Our ambitious goals

• Identify and validate new therapeutic targets in the hardest-to-treat childhood cancers with clear potential for clinical translation.
• Develop and test novel paediatric-specific therapies and treatment approaches that improve efficacy while reducing treatment-related toxicities.
• Advance promising therapeutic candidates through robust preclinical evaluation towards early-phase clinicaltrials in children and adolescents.
• Generate evidence and models of care that support safer, more precise treatment protocols and drive adoption into clinical practice.

Funding for 2026-2027

Applications will open soon for the 2026-2027 round of funding for the Future Leaders Impact Program. Sign up to our mailing list for updates on this funding opportunity.